Novartis is paying $105 million upfront to task Antares Therapeutics with generating small molecules against historically undruggable oncology targets. Antares spun out of Scorpion Therapeutics in ...

– Multi-target collaboration will leverage Antares’ proprietary discovery engine to generate highly selective small molecule medicines against historically undruggable oncology targets – – Antares to ...

June 24 (Reuters) - Antares Therapeutics said on Wednesday it entered a collaboration with Novartis (NOVN.S), opens new tab that could be worth up to about $1.9 billion, aiming to develop therapies ...

Concourse Plaza Multiplex Cinemas in the Bronx is closing its curtains for good Tuesday night after more than three decades in business. In a statement, the movie theater on East 161st Street in ...

A $105 million upfront payment supports joint discovery of first-in-class precision medicines, with potential milestones totaling $1.8 billion linked to development, regulatory, and commercial ...

What is the current share price of Antares Metals Limited (AM5)? Antares Metals Limited's (AM5) current share price is $0.01. This constitutes a price movement of 8.33% when compared to the share ...

SpectraPlex is a comprehensive toolbox for 3D, high-multiplex imaging in spatial biology, available with the STELLARIS microscope. It showcases a streamlined workflow to guide panel creation, automate ...

Novartis and Antares Therapeutics are shooting for the stars, launching a joint mission to develop small molecule oncology therapies. Novartis is paying $105 million cash and offering Antares up to $1 ...

Oncology sales for Novartis grew 18% to $16.8bn in 2025, cementing its status as the big pharma company’s largest therapeutic segment. Credit: Taljat David/Shutterstock.com. Just a year after spinning ...

Japan’s Obayashi Group, one of the country’s five largest construction companies, has announced it will acquire 100% of the shares of UK-headquartered contractor Multiplex from previous owner ...

Multiplex Europe’s construction business reported pre-tax profits down by just over a third last year to £20m from revenue up 16% to £780m. Operating margin at the business also slipped back in 2024 ...

Novartis has spent the last three years — and billions of dollars — loading its pipeline with cancer drug prospects. Among those investments were its acquisitions of MorphoSys and Mariana Oncology in ...